Key result
Resuming OAC in ICH survivors with AF remains uncertain and requires individualized decisions.
Why the study?
Optimal antithrombotic management after intracerebral hemorrhage remains unresolved, especially for patients with atrial fibrillation, with limited high-quality evidence to guide the resumption and timing of oral anticoagulation therapy.
This review provides guidance on the complex clinical decision of whether and when to resume oral anticoagulation in patients with atrial fibrillation who have survived an intracerebral hemorrhage.
Optimal antithrombotic management after intracerebral hemorrhage remains one of the central unresolved issues for patients who survive, especially for those patients with atrial fibrillation. Given the observational nature of the studies regarding anticoagulation resumption after intracerebral hemorrhage, there is uncertainty regarding resumption of oral anticoagulation therapy and its timing. There is limited high-quality evidence to guide clinical practice, leading to significant practice variation and uncertainty for patients and providers. Here, we aim to provide the key elements to guide clinicians in their individual decision: whether or not to start or resume anticoagulation in patients with a history of intracerebral hemorrhage.
No takes yet. Share an insight, caveat, or question.
Puy et al. (2022) conducted a review in Intracerebral hemorrhage with atrial fibrillation. Anticoagulation resumption was evaluated. Resumption of oral anticoagulation therapy in intracerebral hemorrhage survivors with atrial fibrillation remains uncertain due to limited high-quality evidence, requiring individualized decisions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: